Two New TB Vaccines: Safe but Limited Protection

Results from a large-scale clinical trial in India indicate that two new vaccines designed to prevent tuberculosis (TB) are safe for use in both adults and children, although they do not provide protection against all forms of the disease.

The findings, published by The BMJ, highlight the ongoing difficulties in developing a vaccine capable of offering broad and comprehensive protection against TB.

Trial Methodology and Scope

The research was conducted by Indian scientists who studied a group of 12,717 participants. These individuals were all household contacts of patients who had been recently diagnosed with tuberculosis.

As part of the trial, participants were randomly allocated to receive the vaccines or a placebo to evaluate the efficacy and safety of the new candidates.

Vaccine Safety and Performance

The two vaccines evaluated during the study were identified as VPM1002, and Immuvac. According to the trial results, both candidates were found to be safe for administration to both children and adults.

Despite the safety profiles, the vaccines did not meet the goal of broad protection. The study concluded that VPM1002 and Immuvac do not offer protection against all forms of tuberculosis.

Additional Tuberculosis Research

While the human trials for VPM1002 and Immuvac showed limited efficacy, other research into vaccine technologies is ongoing. A separate study reported by Nature examined the use of a novel nanoparticle vaccine.

This nanoparticle vaccine, which displays multistage tuberculosis antigens, was found to confer protection in mice infected with H37Rv. This research represents an earlier stage of development compared to the human clinical trials conducted in India.